^
    7d
    Selective HDAC6 inhibition perturbs autophagy and enhances integrated stress response-mediated immunogenic apoptosis in chronic myeloid leukemia. (PubMed, Biomed Pharmacother)
    The selective HDAC6 inhibitor 7b induced sustained α-tubulin acetylation at lower concentrations than ricolinostat or nexturastat A. 7b reduced primary CML PBMC viability while sparing healthy PBMCs and was active in vivo...ISR activation occurred downstream of the autophagy disruption: rapamycin attenuated ISR activation, whereas ATG7 silencing intensified ISR signaling and apoptosis...The combination elicited immunogenic cell death markers: calreticulin exposure, ATP and HMGB1 release, elevated TNF-α, and reduced IL-8. These findings identify HDAC6-driven autophagy as a therapeutically exploitable vulnerability in CML that, when combined with asciminib, triggers ISR-dependent immunogenic apoptosis.
    Journal
    |
    BCR (BCR Activator Of RhoGEF And GTPase) • MCL1 (Myeloid cell leukemia 1) • BCL2L1 (BCL2-like 1) • TNFA (Tumor Necrosis Factor-Alpha) • CXCL8 (Chemokine (C-X-C motif) ligand 8) • CASP3 (Caspase 3) • HMGB1 (High Mobility Group Box 1) • CALR (Calreticulin) • CASP9 (Caspase 9) • ATF4 (Activating Transcription Factor 4) • ATG7 (Autophagy Related 7) • CASP10 (Caspase 10)
    |
    BCR-ABL1 fusion
    |
    sirolimus • Scemblix (asciminib) • rocilinostat (ACY-1215) • nexturastat A
    7d
    ASCERTAIN: A Real-world Study of Asciminib Effectiveness in Philadelphia Positive Acute Lymphoblastic Leukemia Patients (clinicaltrials.gov)
    P=N/A, N=37, Completed, Novartis Pharmaceuticals
    New trial • Real-world evidence
    |
    ABL1 T315I
    |
    Scemblix (asciminib)
    8d
    ASCIRLI: Efficacy of Asciminib in Real-world in Patients With Chronic Myeloid Leukemia in Second or Subsequent Lines (clinicaltrials.gov)
    P=N/A, N=98, Not yet recruiting, Gruppo Italiano Malattie EMatologiche dell'Adulto
    New trial • Real-world evidence
    |
    Scemblix (asciminib)
    9d
    From Solid Organ Malignancies to Dual Leukaemias: Sequential CLL and CML in a Cancer Survivor. (PubMed, Eur J Case Rep Intern Med)
    Chronic lymphocytic leukaemia (CLL) most commonly transforms into aggressive lymphoma; development of chronic myeloid leukaemia (CML) in a patient with CLL should prompt evaluation for an independent myeloid clone rather than presumed transformation.Myeloid neoplasms in patients with CLL may arise from therapy-related leukemogenesis or divergent evolution from a shared hematopoietic progenitor, highlighting the importance of molecular characterization.Management of coexisting CLL and CML requires individualized risk-benefit assessment, particularly in elderly patients with prior solid tumours and immune dysfunction.
    Journal
    |
    ABL1 (ABL proto-oncogene 1) • BCR (BCR Activator Of RhoGEF And GTPase)
    |
    Imbruvica (ibrutinib) • imatinib • Calquence (acalabrutinib) • Scemblix (asciminib)
    9d
    Asciminib With or Without Sildenafil for Brain Tumors (clinicaltrials.gov)
    P1, N=12, Not yet recruiting, Washington University School of Medicine | Trial completion date: Nov 2027 --> Mar 2028 | Initiation date: Apr 2026 --> Aug 2026 | Trial primary completion date: Oct 2027 --> Feb 2028
    Trial completion date • Trial initiation date • Trial primary completion date
    |
    CRKL (CRK Like Proto-Oncogene, Adaptor Protein) • ABL2 (ABL Proto-Oncogene 2, Non-Receptor Tyrosine Kinase)
    |
    Scemblix (asciminib) • sildenafil
    16d
    PONTHIAC: Safety and efficacy of treatment combination with ponatinib and asciminib in chronic myeloid leukemia patients resistant to ponatinib and/or asciminib (2025-521126-15-00)
    P1/2, N=30, Not yet recruiting, Grupo Espanol De Leucemia Mieloide Cronica (GELMC)
    New P1/2 trial
    |
    ABL1 (ABL proto-oncogene 1)
    |
    Iclusig (ponatinib) • Scemblix (asciminib)
    20d
    Asciminib Used in Consolidation With Imatinib vs. Imatinib to Achieve TFR in CP-CML (clinicaltrials.gov)
    P3, N=8, Terminated, Sarit Assouline | N=164 --> 8 | Trial completion date: Dec 2025 --> Jul 2025 | Active, not recruiting --> Terminated | Trial primary completion date: Dec 2025 --> Jul 2025; Insufficient patient accrual
    Enrollment change • Trial completion date • Trial termination • Trial primary completion date
    |
    ABL1 (ABL proto-oncogene 1) • BCR (BCR Activator Of RhoGEF And GTPase)
    |
    imatinib • Scemblix (asciminib)
    21d
    Chronic myeloid leukemia: incorporation of recent advances into current treatment algorithms. (PubMed, Blood Cancer J)
    In patients experiencing failure of frontline therapy due to resistance or intolerance, multiple second- and third-line options are available, including second-generation TKIs, ponatinib, and asciminib, as well as novel investigational agents, including the ABL1 kinase domain inhibitors olverembatinib and ELVN-001 and the STAMP inhibitors TGRX-678 and TERN-701. In this review, we discuss the recent advances in the treatment of CML-CP and challenge some established management practices.
    Review • Journal
    |
    ABL1 (ABL proto-oncogene 1)
    |
    Iclusig (ponatinib) • Scemblix (asciminib) • Nailike (olverembatinib) • TGRX-678 • ELVN-001 • TERN-701
    23d
    CABL001I12202: Study to evaluate the safety and efficacy of asciminib in pediatric participants with chronic myeloid leukemia. (2025-522138-29-00)
    P1/2, N=14, Not yet recruiting, Novartis Pharma AG
    New P1/2 trial
    |
    ABL1 (ABL proto-oncogene 1)
    |
    Scemblix (asciminib)
    27d
    Phase 1/2 FLAG-IDA, VEN and Asciminib in CML and Ph+ AML (clinicaltrials.gov)
    P1/2, N=30, Not yet recruiting, M.D. Anderson Cancer Center
    New P1/2 trial
    |
    ABL1 (ABL proto-oncogene 1)
    |
    Venclexta (venetoclax) • cytarabine • Blincyto (blinatumomab) • idarubicin hydrochloride • Scemblix (asciminib) • fludarabine IV • Neupogen (filgrastim)
    30d
    CABL001I12202: Study to evaluate the safety and efficacy of asciminib in pediatric participants with chronic myeloid leukemia. (2025-522138-29-00)
    P1/2, N=7, Not yet recruiting, Novartis Pharma AG
    New P1/2 trial
    |
    ABL1 (ABL proto-oncogene 1)
    |
    Scemblix (asciminib)
    1m
    Safety and Efficacy of Asciminib in Pediatrics and Young Adults With Relapse/Refractory (r/r) Philadelphia Positive (Ph+) or ABL-class Ph-like Acute Lymphoblastic Leukemia (ALL) (clinicaltrials.gov)
    P1/2, N=50, Not yet recruiting, Novartis Pharmaceuticals | Trial completion date: Dec 2035 --> Jun 2036 | Trial primary completion date: Jan 2033 --> Jul 2033
    Trial completion date • Trial primary completion date
    |
    ABL1 (ABL proto-oncogene 1) • CD19 (CD19 Molecule)
    |
    ABL1 T315I • ABL2 fusion
    |
    cytarabine • Blincyto (blinatumomab) • vincristine • Scemblix (asciminib)